ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Amyloidosis, Hereditary
Amyloid Neuropathies, Familial
Amyloid Neuropathies
Amyloidosis, Hereditary, Transthyretin-Related
Familial Transthyretin Cardiac Amyloidosis

Interventions

DRUG: Revusiran (ALN-TTRSC)
DRUG: Sterile Normal Saline (0.9% NaCl)

Sponsor

Alnylam Pharmaceuticals